Key clinical point: Patients with migraine respond to preventive treatment with monoclonal antibodies targeting calcitonin gene-related peptide (anti-CGRP mAbs) irrespective of their previous failure or partial response to onabotulinumtoxinA.
Major finding: A response of 50% or higher improvement in headache ( P = .395) or migraine ( P = .408) frequency was not significantly different in partial or complete nonresponders to onabotulinumtoxinA.
Study details: This was a real-world prospective observational study including 155 patients with migraine who initiated preventive treatment with anti-CGRP mAbs and were partial or nonresponders to onabotulinumtoxinA.
Disclosures: The authors declared receiving no financial support for the research, authorship, and/or publication of this article. The authors report no conflicts of interest in relation with this article.
Source: Alpuente A et al. Eur J Neurol. 2021 Mar 17. doi: 10.1111/ene.14828 .